Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination drug** consisting of **hyoscine-n-butylbromide** (also known as hyoscine butylbromide or scopolamine butylbromide) and **ondansetron**. - **Hyoscine-n-butylbromide** is an anticholinergic and antispasmodic agent used to relieve pain and discomfort from smooth muscle spasms in the gastrointestinal, biliary, or genitourinary tracts. It acts by blocking muscarinic acetylcholine receptors on smooth muscle cells, leading to muscle relaxation[2][4][6]. - **Ondansetron** is a selective serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy, radiation, or surgery. It blocks serotonin from stimulating the 5-HT3 receptors in the gut and brain, thereby inhibiting the vomiting reflex[1][5][7]. The combination may be used in clinical practice to manage gastrointestinal symptoms where both smooth muscle spasm and nausea/vomiting are present, although standard fixed-dose products are uncommon.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyoscine-n-butylbromide + ondansetron.